Skip to main content

Table 2 Demographic and baseline characteristics

From: Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial

 

Year 1

 

3 μg ID

(N= 378)

6 μg ID

(N= 375)

15 μg IM

(N= 376)

Total

(N= 1129)

Mean age ± standard deviation

39 ± 11

39 ± 12

39 ± 12

39 ± 12

Male/female ratio

0.6

0.7

1.0

0.7

History of influenza vaccination*, n (%)

112 (29.6)

114 (30.4)

100 (26.6)

326 (28.9)

Reaction to previous influenza vaccination*, n (%)

10 (8.9)

9 (7.9)

7 (7.0)

26 (8.0)

 

Year 2

 

9 μg ID

( N = 544)

15 μg IM

( N = 547)

Total

( N = 1091)

mean age +/- standard deviation

40 ± 12

40 ± 12

40 ± 11

Male/female ratio

0.7

0.7

0.7

 

Year 3

 

9 μg ID

( N = 417)

15 μg IM

( N = 411)

Total

( N = 828)

mean age +/- standard deviation

41 ± 11

40 ± 11

40 ± 11

Male/female ratio

0.8

0.7

0.7

  1. Data are for the per protocol population for Year 1 and the safety population for Years 2 and 3. ID, intradermal; IM, intramuscular; N and n, number of subjects
  2. *Subjects who recalled having previously received an influenza vaccination and having experienced any reactions after a previous influenza vaccination.